Mode
Text Size
Log in / Sign up

BCMA CAR-T therapy achieves 100% MRD negativity in transplant-ineligible multiple myeloma patients.

BCMA CAR-T therapy achieves 100% MRD negativity in transplant-ineligible multiple myeloma patients.
Photo by Ayanda Kunene / Unsplash
Key Takeaway
Consider BCMA CAR-T as a potential option for MRD-negative induction in transplant-ineligible multiple myeloma, pending randomized data.

This Phase II, open-label, single-arm trial enrolled 40 patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for or did not proceed to autologous stem-cell transplantation; 36 patients received the infusion. The intervention consisted of 3-4 cycles of protocol-allowed induction, followed by B-cell maturation antigen (BCMA) CAR-T infusion, and subsequent consolidation and lenalidomide maintenance. The primary outcome was the rate of minimal residual disease (MRD) negativity at Month three postinfusion.

At Month three postinfusion, 36 of 36 patients (100%) achieved MRD negativity (95% CI, 90.3 to 100.0). Complete response (CRR) rates increased from 12 of 36 patients (33.3%) preinfusion to 25 of 36 patients (69.4%) at Month 3, and further to 34 of 36 patients (94.4%) at last follow-up. No MRD recurrence was observed during the follow-up period.

Safety analysis reported transient cytopenia in all patients, including lymphopenia (100%), neutropenia (88.9%), leukopenia (80.6%), thrombocytopenia (19.4%), and anemia (8.3%). Cytokine release syndrome occurred in 52.8% of patients. No deaths or disease progressions occurred during the study. The median follow-up was 15.8 months postinfusion (range, 4.3-26.0 months).

Key limitations include the open-label, single-arm design, which precludes direct comparison to standard care or historical controls. The study population was restricted to transplant-ineligible patients, limiting generalizability to transplant-eligible cohorts. Long-term durability of MRD negativity and overall survival beyond the reported median follow-up remain unknown. These findings suggest potential efficacy but require validation in larger, randomized controlled trials before altering standard practice.

Study Details

Study typePhase2
EvidenceLevel 3
Follow-up816.0 mo
PublishedApr 2026
View Original Abstract ↓
PURPOSE: Patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for or not proceeding to autologous stem-cell transplantation (ASCT)-often because of age or frailty-have limited opportunities to receive multiple effective lines of therapy, underscoring the need for novel frontline strategies. METHODS: In this phase II, open-label, single-arm trial (ClinicalTrials.gov identifier: NCT05860036), patients received 3-4 cycles of protocol-allowed induction, followed by B-cell maturation antigen (BCMA) CAR-T infusion, and subsequent consolidation and lenalidomide maintenance. The primary end point was the rate of minimal residual disease (MRD) negativity (10) at Month three postinfusion. RESULTS: Between April 4, 2023, and December 26, 2024, 43 patients were screened, 40 were enrolled, and 36 received infusion (median age, 68 years [46-75]). In the infused cohort, the MRD negativity rate at Month three postinfusion was 100% (36 of 36; 95% CI, 90.3 to 100.0). With a median follow-up of 15.8 months postinfusion (range, 4.3-26.0), no MRD recurrence was observed. The complete response rate (CRR) increased from 33.3% (12 of 36; 95% CI, 18.6 to 51.0) preinfusion to 69.4% (25 of 36; 95% CI, 51.9 to 83.7) at Month 3% and 94.4% (34 of 36; 95% CI, 81.3 to 99.3) at last follow-up. The most common grade 3 to 4 adverse events were transient cytopenia, including lymphopenia (100%), neutropenia (88.9%), leukopenia (80.6%), thrombocytopenia (19.4%), and anemia (8.3%). Cytokine release syndrome occurred in 52.8% of patients (all grade 1 to 2), immune effector cell-associated neurotoxicity in 5.6% (all grade 1), and infections in 30.6% (grade ≥3 in 19.4%). No deaths or disease progressions occurred by cutoff. CONCLUSION: Frontline BCMA CAR-T therapy induces deep, rapid, and durable remissions with a manageable safety profile in the NDMM population ineligible for or not proceeding to ASCT. These findings support its investigation as a potentially practice-changing strategy for this population.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.